The Journal of Urology
Volume 180, Issue 1 , Pages 373-378, July 2008

Neural Control of Substance P Induced Up-Regulation and Release of Macrophage Migration Inhibitory Factor in the Rat Bladder

  • Pedro L. Vera

      Affiliations

    • Corresponding Author InformationCorrespondence: Research and Development (151), Bay Pines Veterans Affairs Healthcare System, 10000 Bay Pines Blvd., Bay Pines, Florida 33744 (telephone: 727-398-6661, extension 7384; FAX: 727-398-9467).
  • ,
  • Xihai Wang
  • ,
  • Katherine L. Meyer-Siegler

Bay Pines Veterans Affairs Healthcare System, Research and Development, Bay Pines and Department of Surgery, University of South Florida, Tampa, Florida

Received 11 October 2007 published online 21 May 2008.

Purpose

Macrophage migration inhibitory factor is increased in intraluminal fluid after experimental inflammation and it mediates proinflammatory effects on the bladder. We examined the contribution of nerve activity and specific neurotransmitter systems to the mechanism of macrophage migration inhibitory factor release from the bladder during inflammation.

Materials and Methods

Male Sprague-Dawley rats were anesthetized. The bladders were emptied and filled with saline. Rats received saline as a control (0.1 ml/100 gm body weight) or substance P (Sigma®) (40 μg/kg in saline, 0.1 ml/100 gm body weight) subcutaneously as well as hexamethonium (Sigma) (50 mg/kg) intraperitoneally in saline (0.1 ml/100 gm body weight), lidocaine (2%, 0.3 ml) intravesically, atropine (Sigma) (3 mg/kg in saline, 0.1 ml/100 gm body weight) intravenously, propranolol (Sigma) (3 mg/kg in saline, 0.1 ml/100 gm body weight) intravenously or phentolamine (Sigma) (10 mg/kg in saline, 0.1 ml/100 gm body weight) intravenously. After 1 hour the intravesical fluid was removed and the bladder was excised. Macrophage migration inhibitory factor levels in intraluminal fluid were measured by enzyme-linked immunosorbent assay and Western blotting. MIF expression in bladder homogenates was examined using reverse transcriptase-polymerase chain reaction.

Results

Intravesical lidocaine or ganglionic blockage with hexamethonium prevented substance P induced macrophage migration inhibitory factor release. In addition, pretreatment with atropine and phentolamine but not propranolol also prevented macrophage migration inhibitory factor release. While MIF up-regulation in the bladder was increased with substance P treatment, it was only prevented by intravesical lidocaine.

Conclusions

Substance P induced macrophage migration inhibitory factor release in the bladder is mediated through nerve activation. Postganglionic parasympathetic (via muscarinic receptors) and sympathetic (via α-adrenergic receptors) fibers mediate macrophage migration inhibitory factor release, while activating bladder afferent nerve terminals up-regulates MIF.

Key Words: cytokines, cystitis, receptors, muscarinic, receptors, adrenergic, rats, Sprague-Dawley

Abbreviations and Acronyms: ELISA, enzyme-linked immunosorbent assay, MIF, macrophage migration inhibitory factor, PBS, phosphate buffered saline, PCR, polymerase chain reaction, RT, reverse transcriptase, SP, substance P

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Study received local institutional animal care and use committee approval.

 Supported by the Department of Veterans Affairs Merit Award program (PLV, KLMS), National Institute of Diabetes and Digestive and Kidney Diseases DK075059 (XW, PLV, KLMS) and Bay Pines Foundation.

PII: S0022-5347(08)00533-8

doi:10.1016/j.juro.2008.02.040

The Journal of Urology
Volume 180, Issue 1 , Pages 373-378, July 2008